Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $17.30 USD
Change Today -0.07 / -0.40%
Volume 9.7M
BSX On Other Exchanges
New York
As of 8:04 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/27/15 - $18.50
52 Week Low
10/16/14 - $11.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to diagnose and treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides products to treat diseases of the digestive and pulmonary systems; stone management products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices to treat urological and gynecological disorders; spinal cord stimulator systems; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Marlborough, Massachusetts.

24,000 Employees
Last Reported Date: 02/25/15
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $921.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $450.0K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Executive Vice President and President of Rhy...
Total Annual Compensation: $454.1K
Senior Vice President and President of Interv...
Total Annual Compensation: $392.8K
Compensation as of Fiscal Year 2014.

boston scientific corp (BSX) Key Developments

Boston Scientific Collaborates with MedAxiom and TogetherMD to Bring Value Based Solutions to Healthcare Systems

Boston Scientific announced the signing of two strategic agreements to advance the company's efforts to bring value based solutions aimed at improving outcomes and reducing the cost of cardiovascular care delivery to healthcare systems. As part of an agreement with MedAxiom, Boston Scientific will offer programs to help improve the way care is delivered to patients suffering from cardiovascular conditions including heart failure, atrial fibrillation, structural heart and ischemic heart disease. These programs will assist hospitals and ambulatory care sites in developing and implementing comprehensive clinical and operational strategies to drive efficiencies across the care continuum, from diagnosis to treatment and ongoing care. This agreement brings together Boston Scientific's strong expertise in lean practices, process improvement and supply chain optimization with MedAxiom's deep experience in cardiovascular program leadership. Additionally, Boston Scientific has signed an agreement with TogetherMD, to explore the integration of TogetherMD technology into the Boston Scientific cardiovascular portfolio and offer providers with access to actionable data in support of operational improvement and cost reduction initiatives. This includes robust industry benchmarking data and analysis of ongoing operational and financial performance, and billing and coding accuracy. TogetherMD has reported improved reimbursement and average service line cost savings of approximately $1.5 million from the introduction of similar initiatives in single hospital sites.1Boston Scientific will evaluate the use of this information technology platform across its businesses and regions. Boston Scientific will bring these and other comprehensive solutions to healthcare systems through its recently launched ADVANTICS™ solutions brand that emphasizes collaboration to meet unique customer needs. ADVANTICS programs include performance optimization, capital financing, care pathway transformation and patient management.

Boston Scientific Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revised Earnings Guidance for the Year 2015; Provides Earnings Guidance for the Second Quarter of 2015

Boston Scientific Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net sales of $1,768 million against $1,774 million a year ago. Operating income was $24 million against $197 million a year ago. Loss before income taxes was $51 million against income before income taxes of $146 million a year ago. Net loss was $1 million or $0.00 basic and diluted earnings per share against net income of $133 million or $0.10 basic and diluted loss per share a year ago. Adjusted net income was $286 million or $0.21 per diluted share against $268 million or $0.20 per diluted share a year ago. Adjusted net income pre-tax was $327 million against $304 million a year ago. The strong performance in first quarter of 2015 was driven primarily by operational revenue growth and gross margin expansion. Unfavorable foreign exchange impacted first quarter of 2015 adjusted EPS by $0.02 versus the $0.01. Excluding this unfavorable foreign exchange impact, First Quarter adjusted EPS grew 18% year-over-year. Adjusted free cash flow for the quarter was $118 million compared to $161 million last year. Capital expenditures were $46 million compared to $59 million a year ago. The company now estimates revenue for the full year 2015 to be in a range of $7.225 to $7.375 billion compared to prior guidance of $7.300 to $7.500 billion, which versus the prior year period represents change in a range of negative 2 to flat on a reported basis and a growth range of approximately 4% to 6% on an operational basis. The company now estimates income on a GAAP basis in a range of $0.32 to $0.38 per share compared to prior guidance of $0.42 to $0.48, and continues to estimate adjusted earnings, excluding acquisition- and divestiture-, litigation, and restructuring-related charges, pension termination charges, and amortization expense, in a range of $0.88 to $0.92 per share. The company continue to expects full year 2015 adjusted tax rate to be in the range of 13% to 15%. The company expects full year 2015 adjusted operating margin to be between 22% and 22.5%, an improvement of roughly 200 basis points at the midpoint over full year 2014. Previously, the company assumed that unfavorable FX would negatively impact full year 2015 adjusted EPS by $0.04 or $0.01 per quarter. Based on current rates, the company now expects FX to impact full year 2015 adjusted EPS by $0.06 to $0.07 but are not changing adjusted EPS guidance. The company estimates sales for the second quarter of 2015 in a range of $1.800 to $1.850 billion. The company estimates earnings on a GAAP basis in a range of $0.09 to $0.11 per share. Adjusted earnings, excluding acquisition- and divestiture-, and restructuring-related charges, and amortization expense, are estimated in a range of $0.20 to $0.22 per share. On an operational basis, the company expects consolidated sales to grow year-over-year in a range of 4% to 6%. The company expects adjusted gross margin for the second quarter to be in the range of 70.5% to 71.5% prior to key new product launches in the second half of the year. The company expects adjusted operating margin in the second quarter to be between 21% and 22%.

Boston Scientific Corporation Announces Strategic Collaboration with Brainlab AG

Boston Scientific Corporation announced a collaboration with Brainlab AG. The collaboration provides patients and physicians a comprehensive portfolio for Deep Brain Stimulation (DBS) therapy. DBS is intended to treat a variety of disorders, and most commonly may help reduce symptoms for movement disorders such as Parkinson's disease (PD), dystonia, and essential tremor. As part of the agreement, Boston Scientific will begin distributing the Brainlab DBS surgical planning portfolio with the Boston Scientific Vercise DBS System in select countries. DBS therapy involves the placement of a device that stimulates specific areas of the brain using electrical signals. The Vercise DBS System incorporates multiple independent current control, which stimulates targeted areas in the brain selectively and is designed to provide physicians with precise stimulation management. The Vercise DBS System has CE Mark and is available in Europe, Israel, Australia and certain countries in Latin America and Asia Pacific for the treatment of PD, tremor and dystonia.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $17.30 USD -0.07

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $141.08 USD -0.92
Olympus Corp ¥4,260 JPY -60.00
St Jude Medical Inc $71.07 USD -0.26
Stryker Corp $92.56 USD -0.34
Zimmer Holdings Inc $110.10 USD -0.41
View Industry Companies

Industry Analysis


Industry Average

Valuation BSX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 3.6x
Price/Cash Flow 123.1x
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at